Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma

Stopped This study was terminated early due to funding issues prior to completion of phase I

Conditions

• Malignant Glioma (WHO Grade III or IV)

Interventions

• DRUG: CTO
• DRUG: Lomustine

Sponsor

Annick Desjardins

Collaborators

• [object Object]